Rats with unilateral dopamine-denervating lesions sustained a 3-week treatment with a daily L-DOPA dose that is in the therapeutic range for Parkinson's disease. In most of the treated animals, chronic L-DOPA administration gradually induced abnormal involuntary movements affecting cranial, trunk, and limb muscles on the side of the body contralateral to the lesion. This effect was paralleled by an induction of FosB-like immunoreactive proteins in striatal subregions somatotopically related to the types of movements that had been elicited by L-DOPA. The induced proteins showed both regional and cellular colocalization with prodynorphin mRNA. Intrastriatal infusion of fosB antisense inhibited the development of dyskinetic movements that were related to the striatal subregion targeted and produced a local specific downregulation of prodynorphin mRNA. These data provide compelling evidence of a causal role for striatal fosB induction in the development of L-DOPA-induced dyskinesia in the rat and of a positive regulation of prodynorphin gene expression by FosB-related transcription factors.
INTRODUCTION
The dopamine (DA) precursor molecule, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is currently the most effective pharmacotherapy for Parkinson's disease. However, long-term L-DOPA treatment is hampered by serious complications, among which the occurrence of dyskinesias (abnormal involuntary movements) can be particularly debilitating. It has been suggested that both the progressive degeneration of nigral DA neurons and the postsynaptic changes in dopaminoceptive brain structures contribute to the development of L-DOPA-induced dyskinesia (Mouradian et al., 1989) . Indeed, a body of studies performed in both rodent and primate models of Parkinson's disease (Doucet et al., 1996; Brotchie et al., 1998; Cenci et al., 1998; and references therein) has shown that chronic treatment with DA agonists alters the expression of genes encoding for neuromodulators and/or transcription factors in striatal neurons, which constitute the major target of ascending DA projections. However, causal links between the molecular and the adverse motor effects produced by chronic L-DOPA treatment await demonstration.
We have recently found that unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats, sustaining repeated injections of a low daily L-DOPA dose, can develop abnormal, purposeless movements affecting several muscle groups on the side of the body contralateral to the lesion. As reported previously (Cenci et al., 1998) , such movements develop gradually after a variable latency period from the onset of chronic L-DOPA treatment, and their time course after a single L-DOPA dose simulates peak-dose dyskinesia in Parkinson's disease. These and other similarities suggest that 1 These authors contributed equally to this work. 2 To whom correspondence should be addressed.
